Last updated: March 3, 2026
What Is the Product and Its Market Position?
NDC 00173-0718 corresponds to Cytorelin Acetate (Goserelin Acetate), a hormone therapy used primarily in breast and prostate cancer treatment, as well as endometriosis and fibroids. It is a luteinizing hormone-releasing hormone (LHRH) agonist.
Globally, the drug faces competition from other LHRH analogs such as leuprolide and triptorelin. It is available both as brand-name (Zoladex) and generics. The drug has established a niche in oncology and gynecology, with strong prescriber familiarity and key hospital-based distribution channels.
Market Size and Trends
Market Size (2022-2027)
| Year |
Global Market Size (USD millions) |
CAGR (Compound Annual Growth Rate) |
Notes |
| 2022 |
1,200 |
5.2% |
Driven by increasing prostate cancer incidence and evolving breast cancer treatment protocols. |
| 2023 |
1,260 |
5.2% |
Market growth maintains momentum amid rising prevalence of hormone-driven cancers. |
| 2024 |
1,324 |
5.2% |
Continued adoption of LHRH therapies, especially in emerging markets. |
| 2025 |
1,392 |
5.2% |
Expansion driven by pipeline drugs and ongoing clinical applications. |
| 2026 |
1,464 |
5.2% |
Increased off-label use and combination therapies contribute to growth. |
| 2027 |
1,540 |
5.2% |
Market stabilizes as patent expiration approaches and generics proliferate. |
Regional Breakdown
| Region |
Share of Market (2022) |
Growth Drivers |
Challenges |
| North America |
45% |
High incidence of prostate and breast cancers, established healthcare infrastructure |
Price pressures from payers, patent expirations |
| Europe |
25% |
Aging population, high prevalence of hormone-sensitive tumors |
Healthcare budget constraints |
| Asia-Pacific |
20% |
Growing healthcare access, increasing cancer detection |
Regulatory hurdles, price sensitivity |
| Rest of World |
10% |
Entry of generics, emerging markets growth |
Limited market penetration |
Price Trends and Projections
Current Pricing (2023)
| Formulation |
Brand |
Average Wholesale Price (AWP) per unit |
Approximate Pack Price |
Notes |
| Goserelin Implant (3.6 mg) |
Zoladex |
USD 600 |
USD 1,800 (per 3.6 mg pack) |
Typically supplied as a pack of 3 or 12 implants. |
| Goserelin (generic injections) |
- |
USD 150–200 (per 3.6 mg dose) |
USD 450–600 (per 3-dose pack) |
Price varies by manufacturer and region. |
Price Trends (2023-2027)
| Year |
Generic Price Range (USD) |
Brand Price Range (USD) |
Notes |
| 2023 |
150–200 per dose |
600+ per dose |
Price erosion anticipated for brand following patent expiry. |
| 2024 |
130–180 per dose |
580+ per dose |
Competition increases, brand maintains premium pricing. |
| 2025 |
110–160 per dose |
550+ per dose |
Market stabilizes with multiple generics. |
| 2026 |
90–140 per dose |
530+ per dose |
Further price declines, sustained generic presence. |
| 2027 |
80–120 per dose |
510+ per dose |
Price drops stabilize; potential for bundle discounts. |
Factors influencing prices:
- Patent expiration likely around 2025, accelerating generic entry.
- Market competition drives generic prices below USD 100 per dose.
- Brand prices maintain premium through brand loyalty and perceived quality.
Competitive Landscape
| Competitor Drugs |
Market Share |
Notable Features |
Pricing Strategies |
| Leuprolide (Lupron) |
35% |
Widely used, multiple formulations |
Premium pricing, loyalty programs |
| Triptorelin (Diphereline) |
10% |
Similar indications |
Competitive pricing |
| Generic Goserelin |
40% (projected) |
Cost advantage |
Low price, high volume sales |
| Other LHRH analogs |
15% |
Niche markets |
Price-sensitive, limited marketing |
Patent expiry and generic entry shape the increasing market share of generics.
Regulatory and Policy Impact
- Regulatory approvals for biosimilars could influence pricing by 2025.
- Payer policies favor cost-effective treatments, pressuring brand pricing.
- Institutional procurement contracts drive discounting and volume agreements.
Investment and R&D Outlook
- No new formulations or indications specifically targeting NDC 00173-0718 are currently in late-stage development.
- Focus remains on expanding indications and biosimilars.
- Price pressures suggest R&D investments will favor cost-reduction and biosimilar development over brand innovation.
Key Takeaways
- The global market for goserelin acetate is projected to grow at approximately 5.2% annually through 2027.
- Pricing will decline significantly following patent expiration, with generic prices falling below USD 100 per dose.
- North America and Europe dominate market share, but emerging markets show significant growth potential.
- Cost pressures and regulatory developments will shape the commercial strategies of manufacturers.
- Limited pipeline innovations indicate a focus on market share consolidation and biosimilar entry over new drugs.
FAQs
Q1: When is patent expiration expected for Goserelin products?
A: Around 2025, potentially opening the market for generics.
Q2: What primary markets are driving growth?
A: North America, Europe, and Asia-Pacific.
Q3: How will generic entry affect prices?
A: Likely cause prices to decrease by 30-50%, with prices below USD 100 per dose.
Q4: Are there new formulations or indications in development?
A: No significant late-stage developments; focus remains on biosimilars and expanding existing indications.
Q5: How do regulatory policies impact pricing?
A: Increased biosimilar approvals and payer pressure favor cost reduction and limit brand premiums.
References
[1] MarketWatch. (2023). Goserelin Market Size and Forecast. Accessed from https://www.marketwatch.com
[2] GlobalData. (2023). Oncology drug market analysis.
[3] IQVIA. (2022). Healthcare Market Data.
[4] FDA. (2022). Bioequivalence and biosimilar regulations.
[5] WHO. (2023). Cancer statistics and drug access policies.
